At RSNA 2013, Sony will be showing a works-in-progress medical recorder, the HVO-500MD (without DVD optical drive) and the HVO-550MD (with DVD optical drive). These models are designed specifically for medical recording.

Toshiba is introducing a new Aquilion One platform at RSNA 2013. The new Aquilion One family allows providers to more precisely choose the system that fits their needs today while giving them an upgrade path for the future.

September 9, 2013 — Toshiba’s new Aquilion Prime is a versatile, scalable and patient-friendly computed tomography (CT) system. The system’s technologies are built for the clinical and financial needs of users both in the present and future.

September 9, 2013 — Keystone Heart, a company in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced its TriGuard cerebral protection device has received CE mark, enabling the company to commercially market the TriGuard in Europe and other territories.

The U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for Siemens’ Symbia Intevo, the first system to completely integrate high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of computed tomography (CT) into a single modality, rather than imaging as separate overlay images.

At the 2013 Radiological Society of North America’s annual meeting (RSNA 2013), aycan, a provider of cost-saving PACS solutions, will highlight new release plugins for its post-processing workstation, aycan OsiriX PRO, which significantly expands the functionality of its specialty workstations for mammography, oncology and vascular surgery. 

Cardiac stents to open blocked heart arteries and reduce chest pain have been used for decades. However, cardiologists have never been certain that women benefitted from their use because clinical trials testing stents only included, at most, 25 percent women, making the overall findings mostly relevant to just men.

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study was released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now